Rabjohns Jennifer L A, Park Yoon-Dong, Dehdashti Jean, Henderson Christina, Zelazny Adrian, Metallo Steven J, Zheng Wei, Williamson Peter R
Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
J Biomol Screen. 2014 Feb;19(2):270-277. doi: 10.1177/1087057113496847. Epub 2013 Jul 29.
Cryptococcus neoformans is a pathogenic fungus that causes meningitis worldwide, particularly in human immunodeficiency virus (HIV)-infected individuals. Although amphotericin B is the "gold standard" treatment for cryptococcal meningitis, the toxicity and inconvenience of intravenous injection emphasize a need for development of new anticryptocccal drugs. Recent data from humans and animal studies suggested that a nutrient-deprived host environment may exist in cryptococcal meningitis. Thus, a screening assay for identifying fungicidal compounds under nutrient-deprived conditions may provide an alternative strategy to develop new anticryptococcal drugs for this disease. A high-throughput fungicidal assay was developed using a profluorescent dye, alamarBlue, to detect residual metabolic activity of C. neoformans under nutrient-limiting conditions. Screening the Library of Pharmacologically Active Compounds (LOPAC) with this assay identified a potential chemical scaffold, 10058-F4, that exhibited fungicidal activity in the low micromolar range. These results thus demonstrate the feasibility of this alamarBlue-based assay for high-throughput screening of fungicidal compounds under nutrient-limiting conditions for new anticryptococcal drug development.
新型隐球菌是一种致病性真菌,在全球范围内可引发脑膜炎,尤其是在感染人类免疫缺陷病毒(HIV)的个体中。尽管两性霉素B是治疗隐球菌性脑膜炎的“金标准”,但其静脉注射的毒性和不便凸显了开发新型抗隐球菌药物的必要性。来自人类和动物研究的最新数据表明,隐球菌性脑膜炎患者体内可能存在营养匮乏的宿主环境。因此,在营养匮乏条件下鉴定杀真菌化合物的筛选试验,可能为开发针对该疾病的新型抗隐球菌药物提供一种替代策略。利用一种前荧光染料alamarBlue开发了一种高通量杀真菌试验,以检测新型隐球菌在营养限制条件下的残余代谢活性。用该试验筛选药理活性化合物文库(LOPAC),鉴定出一种潜在的化学骨架10058-F4,其在低微摩尔范围内表现出杀真菌活性。因此,这些结果证明了这种基于alamarBlue的试验在营养限制条件下高通量筛选杀真菌化合物以开发新型抗隐球菌药物的可行性。